LONDON -- The newly appointed executive chairman of Aviva
But John McFarlane's frankness may mark a new era at the only composite insurer in the FTSE 100
If McFarlane can pull off his plans and maintain the payout, then shareholders will finally see the value in the company realized. It's been a nerve-wracking 12 months, with the shares down 35%, while the FTSE 100 has dropped just 6%.
There's no question that Aviva is in a mess. Its own management says it has weaker and more volatile capital than its peers; an overly complex and bureaucratic structure; overexposure to traditional capital-intensive products in low-growth markets and the eurozone in particular; and a history of too many strategic changes, unsuccessful restructurings, and opaque communication.
To turn the business -- any business -- around requires capable management, a sound strategy, effective execution, and a forgiving external environment. Recent developments suggest the first three are in place, though the company remains at the mercy of the eurozone.
McFarlane has certainly turned in an impressive performance in his first two months. He became executive chairman this month, parachuted in as executive deputy chairman in May after former CEO Andrew Moss was ousted in the "Shareholder Spring" that saw the departure of several overpaid but underperforming FTSE 100 executives.
Also significant is the appointment of David McMillan, former head of the U.K. and Ireland, to the post of director of group transformation, charged with implementing the new plan. In plain words, he is interim CEO.
McFarlane's fast action forestalls the danger of Aviva being seen as rudderless at a vulnerable time, which could have made it a takeover candidate. But it complicates the challenge of finding a permanent CEO, who will have to be happy implementing the course of action already set out.
The strategy is one of significant retrenchment. The aim is to focus on fewer businesses where higher returns can be achieved. Aviva has undertaken a textbook analysis of its 58 business segments and identified 16 of them that consume 38% of its capital but contribute just 18% of its operating profit after tax. These will be sold or run down.
A relatively low and volatile capital base is one of the reasons behind Aviva's low share price. It will now target internal economic capital levels of 160% to 175% of the minimum required. The aim is to achieve this through disposals and better capital rationing. A dividend cut or new equity raising would be the last resort.
And the insurer aims to take the knife to middle management, cutting down the layers between the CEO and operational staff from nine to five in order to save 400 million pounds by the end of 2012. Total staff costs were 1.3 billion last year, so that's a sizeable challenge.
The new strategy was immediately followed by an announcement of the sale of half of Aviva's remaining holding in Delta Lloyd, which is listed on the NYSE Euronext Amsterdam exchange. That yielded 380 million pounds but, more importantly, reduced the holding below 20%, where it will have less impact on Aviva's capital.
Reuters also reported that the sale of Aviva's Malaysian joint venture, which is expected to raise about $500 million, is progressing well, with four potential buyers through to the second stage.
The big question mark is Aviva's U.S. operation. Bought for 2 billion pounds in 2006, it would transform Aviva's capital position if McFarlane could pull off a quick sale.
But of course, the external environment is out of the company's control. Aviva is significantly exposed to the eurozone, through both its investments and the amount of business it conducts in France, Spain, and Italy. Its share price often acts as a barometer of sentiment toward the region.
So a blow-up in the eurozone would spell disaster for the company. Barring that, it looks as if the company might just get away with maintaining the payout.
Still, there's a real risk of a cut. Aviva is a racy share. For widows, orphans, and those of the more nervous disposition, there are safer bets on the FTSE 100 that still have juicy yields. Standard Life and Legal and General, both life assurers with long heritages, yield 5.9% and 5.1%, respectively. That's a decent payout from companies that have much less downside risk than Aviva, though they lack Aviva's recovery potential.
Baffled by shares? This special report -- "What Every New Investor Needs To Know" -- can start you on the path to investing. What's more, the report is free!
Further Investment Opportunities